Nadia's Feed
Nov 13, 2014

Halliburton in talks to buy Baker Hughes -source

Nov 13 (Reuters) – Oilfield services provider Halliburton Co
is in talks to buy rival Baker Hughes Inc, a
person familiar with the matter said on Thursday, but any
potential deal could run into antitrust concerns.

Officials at Baker Hughes and Halliburton, both based in
Houston, declined to comment on the talks, which were first
reported by Dow Jones and in The Wall Street Journal. The person
familiar with the matter spoke to Reuters on condition of
anonymity.

Nov 12, 2014

Exclusive: Some unhappy Yahoo investors asking AOL for rescue

NEW YORK (Reuters) – At least two top-10 Yahoo Inc shareholders are so unhappy with Chief Executive Marissa Mayer’s turnaround efforts that they are making a direct plea to AOL Inc CEO Tim Armstrong to explore a merger and run the combined company.

Their move follows an activist campaign by hedge fund Starboard Value LP, which is pushing Yahoo to consider a deal with AOL and unlock Yahoo’s valuable stakes in Asian Web companies.

Nov 12, 2014

EXCLUSIVE: Some unhappy Yahoo investors asking AOL for rescue

NEW YORK (Reuters) – At least two top-10 Yahoo Inc shareholders are so unhappy with Chief Executive Marissa Mayer’s turnaround efforts that they are making a direct plea to AOL Inc CEO Tim Armstrong to explore a merger and run the combined company.

Their move follows an activist campaign by hedge fund Starboard Value LP, which is pushing Yahoo to consider a deal with AOL and unlock Yahoo’s valuable stakes in Asian Web companies.

Nov 7, 2014

Salix inventory issues sink deal with Allergan

Nov 6 (Reuters) – Salix Pharmaceuticals Ltd slashed
its full-year forecast on Thursday and said inventory for its
key drugs piled up, an issue that people familiar with the
matter said dissuaded Allergan Inc Inc from acquiring
the drugmaker.

The two companies were close to inking a deal, but Botox
maker Allergan balked after its due diligence raised questions
over inventory levels, the people said, requesting anonymity
because the negotiations were confidential.

Nov 3, 2014

Allergan says has been approached by another party about a deal

Nov 3 (Reuters) – Botox maker Allergan Inc, which is
fending off an acquisition by Valeant Pharmaceuticals Inc
, said on Monday it had been approached by another party
regarding a potential transaction.

The company is Actavis Plc, a source familiar with
the situation said.

Allergan, which made the disclosure in a regulatory filing
on Monday, had said it was looking for acquisitions but has not
previously said it had been contacted about a deal.

Oct 15, 2014

Exclusive: Tech firms HP, EMC call off merger talks – sources

NEW YORK (Reuters) – Hewlett-Packard Co has ended merger talks with EMC Corp and may announce this development as soon as Wednesday, deciding to walk away after months of fruitless negotiations, people briefed on the matter told Reuters.

The official cessation of discussions to merge two of the tech industry’s largest enterprise-oriented firms may come as a disappointment to activist investors Elliott Management, which has pushed hard for storage products maker EMC to pursue merger or spinoff opportunities.

Oct 8, 2014

Actavis may reap benefits of Valeant’s hard work on Allergan

NEW YORK, Oct 8 (Reuters) – Earlier this week, Canada’s
Valeant Pharmaceuticals International Inc appeared to
have its plan to buy Botox maker Allergan Inc all mapped
out.

The next phase in Valeant’s months-long campaign to acquire
Allergan for about $53 billion in cash and stock was to
announce “blow-out” earnings on Oct. 20, which would have led to
a jump in its share price and, therefore, the value of its bid,
according to people familiar with the situation.

Oct 7, 2014

Exclusive: Actavis plans new merger approach for Allergan – sources

NEW YORK (Reuters) – Actavis Plc (ACT.N: Quote, Profile, Research, Stock Buzz) plans to approach Allergan Inc (AGN.N: Quote, Profile, Research, Stock Buzz) again about a potential merger, as the Botox maker warms up to the possibility of a sale, people familiar with the matter said on Tuesday.

Allergan, which has repeatedly rejected offers from Valeant Pharmaceuticals International Inc (VRX.TO: Quote, Profile, Research, Stock Buzz), would consider a takeover proposal that values the company at above $200 per share, some of the people said.

Oct 7, 2014

Actavis plans new merger approach for Allergan -sources

NEW YORK, Oct 7 (Reuters) – Actavis Plc plans to
approach Allergan Inc again about a potential merger, as
the Botox maker warms up to the possibility of a sale, people
familiar with the matter said on Tuesday.

Allergan, which has repeatedly rejected offers from Valeant
Pharmaceuticals International Inc, would consider a
takeover proposal that values the company at above $200 per
share, some of the people said.

Oct 7, 2014

Exclusive: Hubbell trustee reviews options for controlling stake- sources

NEW YORK (Reuters) – The trustee of Hubbell Inc’s (HUBb.N: Quote, Profile, Research, Stock Buzz)(HUBa.N: Quote, Profile, Research, Stock Buzz) controlling family trusts is evaluating alternatives for their holdings, which could lead to a shakeup at the $7.2 billion U.S. electrical equipment maker, according to people familiar with the matter.

The trustee, which oversees family trusts that control a significant portion of Hubbell’s voting power, has tapped Credit Suisse Group (CSGN.VX: Quote, Profile, Research, Stock Buzz) to review options for the shares, the people said this week. They asked not to be named because the matter is not public.